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Objectives: Dasatinib 100 mg daily and nilotinib 600/800 mg daily have been compared to imatinib as first line
treatments for CML in two recent randomised studies. However, no head to head evidence exists of the relative
efficacy of dasatinib and nilotinib.
Methods: We conducted a systematic literature review and used the data extracted to perform an indirect
comparison meta-analysis of the three interventions.
Results: Data from eight clinical studies (3,520 individuals) were included, all of which were of good quality
(low risk of bias). At six months, the odds of complete cytogenetic response (CCyR) for dasatinib and nilotinib were
approximately three times those for imatinib (range 2.77 to 3.06, all values not significant). At twelve months
datatinib and nilotinib were significantly better than imatinib for both CCyR and major molecular response (MMR)
(CCyR odds range 2.06 to 2.41, MMR odds range 2.09 to 2.87). At eighteen months dasatinib and nilotinib were
again significantly better in terms of CCyR than imatinib (response odds 1.55 to 2.01). When dasatinib and nilotinib
were compared to each other, for both clinical endpoints at all time points the response odds were not
significantly different.
Conclusions: On the basis of a systematic review of the current literature base, dasatinib 100 mg, nilotinib 600 mg
and nilotinib 800 mg should be viewed as equivalent in terms of complete cytogenetic and major molecular
response.
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Chronic myeloid leukemia (CML) is a leukemia
characterised by the t(9:22) translocation known as the
Philadelphia chromosome. The annual incidence rate of
CML is 1–2 per 100,000 people [1]. The majority
of diagnoses are made in the chronic disease stage
(CP-CML) as opposed to the accelerated or blastic
stages [2,3].
Historically, while an allogeneic stem cell transplant
offered the greatest chance of long term survival,
individuals ineligible for transplant would be offered* Correspondence: stuart.mealing@oxfordoutcomes.com
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reproduction in any medium, provided the orinterferon-alfa (IFN-α), hydroxyurea or chemotherapy as
first line therapy. Due to the largely palliative nature of
these interventions – in particular hydroxyurea – the
prognosis for patients receiving these treatments is poor,
with expected survival of four to six years [2,3].
European LeukemiaNet and NCCN guidelines how-
ever, recommend that newly diagnosed individuals com-
mence therapy with imatinib (Gleevec™, Novartis), an
inhibitor of the oncogenic BCR-ABL protein present in
CML, at a dose of 400 mg per day [4,5]. The efficacy of
this product compared to interferon usage was
demonstrated in the International Randomised Study of
Interferon and STI571 (IRIS) [6]. Long term follow up
studies from IRIS have highlighted the long termThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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techniques have been used to extrapolate the data from
IRIS, resulting in predicted mean survival estimates of
approximately 20 years in patients who respond to treat-
ment [10,11].
Recently, two second generation tyrosine kinase
inhibitors (TKIs) have been developed (dasatinib,
Bristol-Myers Squibb and nilotinib, Novartis) and repre-
sent viable alternatives to imatinib. These products were
initially launched for use as second line therapies and
were approved for first line use by the US Food and
Drug Administration and the European Medicines
Agency in 2010 on the basis of the results from two on-
going multinational RCTs [12,13].
In the Dasatinib versus Imatinib Study in Treatment
Naïve CML Patients (DASISION) clinical trial [13], 519
individuals were randomised (1:1) to receive either
dasatinib 100 mg or imatinib 400 mg daily. At 12 -
months, dasatinib was statistically superior in terms of
both major molecular response (MMR, p = 0.007) and
complete cytogenetic response (CCyR) (p < 0.001).
Nilotinib 600 mg and 800 mg daily were compared to
imatinib 400 mg daily in the Evaluating Nilotinib Effi-
cacy and Safety (ENESTnd) clinical trial [12]. Random-
isation was 1:1:1 and nilotinib was statistically superior
at one year on the same endpoints (p < 0.001 for all
comparisons).
Despite the demonstrable link between response to
treatment and survival [8,14-16] agencies such as the
United Kingdom’s National Institute for Health and
Clinical Excellence (NICE) and the Canadian Agency for
Drugs and Technologies in Health (CADTH) as well as
private entities such as the Academy of Managed Care
Pharmacy (AMCP) in the United States use both clinical
and economic information in their assessment process
[17-19]. In particular, estimates of relative efficacy are
required in order to assess whether or not the additional
benefits of a particular drug compared to another out-
weigh the additional costs. In this context, ‘benefit’ can
refer to life years gained, Quality-adjusted life years
gained (QALYs) or any other clinical endpoint.
At the time of manuscript preparation, there are no
published randomised or observational head to head
trials of dasatinib and nilotinib in newly diagnosed CML
to inform decision making at either the payer (national)
or prescriber (local) level. Further, any reimbursement
decisions relating to the treatment of newly diagnosed
CML will inevitably focus on the relative efficacy of both
interventions compared to current standard treatment
(imatinib 400 mg) as well as compared to each other.
We therefore undertook a systematic review of the lit-
erature on first line treatment to identify all randomised
controlled trials of first line dasatinib, nilotinib and
imatinib, and used the results from this review togenerate relative efficacy estimates for key measures of
treatment efficacy (CCyR and MMR) at as many time
points as possible, using an indirect comparison meta-
analysis. The results from this analysis will help all
stakeholders overcome the lack of head to head data in
making either reimbursement or prescribing decisions.
Materials and methods
Evidence identification
The Medline, Medline in Process and EMBASE
databases were searched through the OVID SP portal.
Database search strategies were designed using MeSH
and Emtree terms respectively relating to CML, the
treatments of interest and a randomised controlled trial
filter. Restrictions were only made on studies published
from 1980, publication language (English only) and
population (adults greater than 18 years old). The search
terms are reproduced in full in Additional file 1. In order
to ensure the evidence network was as comprehensive as
possible, relevant literature search terms were included
for other interventions (i.e. interferon, hydroxyurea).
Conference proceedings from the 2009 and 2010
American Society of Hematology (ASH) and American So-
ciety of Clinical Oncology (ASCO) and the 2009 European
Hematology Association (EHA) annual meetings were
searched. In order to be as inclusive as possible, the project
sponsors (Bristol-Myers Squibb, BMS) were invited to pro-
vide any as yet unpublished material for potential inclusion
into the review.
In addition to type of publication and treatment op-
tion, the inclusion criteria used covered the need to re-
port information on one of the endpoints of interest
(CCyR, MMR) at any time point. Reasons for exclusion
were non-randomisation, non-comparativeness, pharma-
cokinetic studies, animal/in vitro studies or publications
without an available abstract.
Abstracts and sponsor-provided literature were inde-
pendently screened by two reviewers against the formal
inclusion criteria. Full papers were screened by two
reviewers against the same inclusion/exclusion criteria
used in the initial screening, with a third reviewer pro-
viding a casting vote where no consensus occurred. Data
was then extracted into an ExcelW workbook by one re-
viewer and checked by another.
The quality of all included articles was assessed using
a series of bespoke questions derived from the Cochrane
Handbook for Systematic Review of Interventions [20]. A
description of the method used for the quality assess-
ment is included in Additional file 1.
Evidence synthesis
Indirect comparison (network) meta-analysis is an ex-
tension of conventional, pair-wise meta-analysis [21-25].
A statistical analysis of the network of trial evidence is
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ness for a range of treatments. Both direct (i.e. head to
head) and indirect evidence is used in this approach to
evidence synthesis. Network meta-analysis is based on
the assumption that, on a suitable scale, the difference in
effect between treatments A & B is equal to the differ-
ence in effects between treatments A & C and B & C.
The analysis can be expanded to more complex
networks of evidence through the inclusion of additional
interventions.
Studies have shown that the results from a network
meta-analysis are consistent with those from a conven-
tional meta-analysis [26] and, by their need for an
assumed commonality of treatment effect modifiers
across all included studies, respect randomisation in
each individual trial. Of note, is that implicit in conven-
tional meta-analyses is the assumption of either a com-
mon treatment effect or study-specific treatment effects
distributed around a typical value [26].
A fixed-effects approach (i.e. common treatment ef-
fect) was used to estimate the probability of response at
each time point. Given that it is the current standard of
care, imatinib 400 mg daily was the baseline comparator
against which all relative efficacy estimates were
calculated. All calculations were performed on the log-
odds scale, and hence results are expressed in terms of
odds and absolute probability estimates.
The network meta-analysis was implemented in the
WinBuGS and R software packages [27,28], with two
Markov Chain Monte-Carlo chains used starting from
different initial values of select unknown parameters.
Each chain contained 20,000 burn-in iterations followed
by 100,000 update iterations. Convergence was assessed
by visualising the histories of the chains against the iter-
ation number, since overlapping histories that appear
to mix with each other provide an indication of
convergence.
Since this approach is inherently Bayesian, initial
values (‘priors’) are required to initiate the analysis, and
we used non-informative Normal functions in order to
have the results solely reflect the data used in the ana-
lysis, and not any a priori belief in the results. Inferences
on the relevant parameters are based on the conver-
gence of the derived posterior distributions. The accur-
acy of the posterior estimates was assessed via the
calculation of the Monte Carlo error for each parameter.
Results
Total number of studies identified
The initial searches were performed on 9th November
2009 and were updated on 18th June 2010 and 31st
March 2011. After the elimination of duplicates, the
EMBASE and MEDLINE searches identified a total of
2,024 abstracts of potential interest. The conferencesearches identified a further 534 potentially relevant
publications. BMS made seven further articles and
abstracts available. Following formal review, information
reported in a total of 16 articles that relate to eight dis-
tinct clinical studies were also included in the analysis
[12,13,29-41]. A summary of all included studies is
presented in Table 1. Information derived from 3,520
individuals was used to inform the NMA.
Of the abstracts and articles initially made available by
BMS, two were dasatinib related manuscripts that were
in the peer-review process and one was a separate
manuscript in the development stage. In addition, three
were abstracts subsequently presented at clinical
conferences. All of these are now in the public domain
and hence were identified during the search updates
[29,31,38]. The final article related to the use of nilotinib
in a non-randomised cohort of individuals and was thus
excluded from the meta-analysis.
Five of the included studies compared imatinib at
standard (400 mg daily) and high dose (600 mg/
800 mg daily) [32-34,39-41] and these were included
in the evidence network for reasons of completeness.
Two studies compared dasatinib 100 mg daily to
imatinib 400 mg daily [13,29-31,38] and one compared
nilotinb 600 mg/800 mg daily to imatinib 400 mg daily
[12,35-37].
Meaningful evidence networks were created for CCyR
at six, 12 and 18 months and for MMR at 12 months
only (Figure 1). Information on CCyR was reported in
seven studies at six and 12 months and in four studies at
18 months, and data on MMR at 12 months in seven
studies (Table 2). With the exception of a general lack of
reporting of methods used for blinding and conceal-
ment, the included studies are of good quality (i.e. low
risk of bias) (Table 1).
Complete cytogenetic response (compared to Imatinib)
At both six and 12 months, the reported CCyR probabil-
ities for imatinib in the DASISION study were higher
than in all other observed trials.
At six months the odds of response for both dasatinib
and nilotinib was approximately three times higher than
for imatinib 400 mg daily, although these results were
not significant (dasatinib 100 mg 2.98 [95% CrI 0.45 to
9.76], nilotinib 600 mg 3.06 [95% CrI 0.42 to 9.85],
nilotinib 800 mg 2.77 [95% CrI 0.38 to 8.82]; Table 3). In
addition, the derived probabilities show a high level of
uncertainty, which arose due to the weak evidence net-
work (dasatinib 100 mg 55.3% [95% CrI 22.9% to 86.7%],
nilotinib 600 mg 60.7% [95% CrI 21.9% to 86.8%],
nilotinib 800 mg 56.8% [95% CrI 20.4% to 85.5%]). How-
ever, by 12 months more robust evidence networks were
created and as a result of the associated narrowing of all
credible intervals the probability of response compared
Table 1 Description of included studies













Q1 Q2 Q3 Q4 Q5 Q6
DASISION [13,29-31] Multicentre,
Randomised, Phase III
Dasatinib 100 mga 259 18.0 99 mg 15% Yes No Yes No Yes Yes
Imatinib 400 mga 260 400 mg 19%
Baccarani et al. [32] Prospective,
randomised
12 Imatinib 400 mga 108 26 400 mg No Yes No Yes Yes No
Imatinib 800 mga 108 26 720 mg
German CML Study IV
[33,34]
Randomised 36 Imatinib 800 ga 338 40 646 mg Yes No No No No No
Imatinib 400 ga 326 40 400 mg
ENESTed [12,35-37] Multicentre,
Randomised, Phase III
60 Nilotinib 300 mgb 282 18 592 mg 16% Yes No Yes No Yes Yes
Nilotinib 400 mgb 281 18 779 mg 18%
Imatinib 400 mga 283 18 400 mg 21%
S0325 Intergroup [38] Open Label,
Randomised, Phase II
12 Imatinib 400 mga 127 Yes No No No No No
Dasatinib 100 mga 126
ISTAHIT [39] Multicentre,
Randomised, Phase III
24 Imatinib 400 mga 114 12.75 400mg Yes No Yes No Yes Yes
Imatinib 800 mga 113 12.75 767 mg
Cortes et al. [40] Multicentre,
Randomised, Phase III
12 Imatinib 400 mga 157 17 0% No No Yes No Yes Yes
Imatinib 400 mga 319 17 0.6%
SPIRIT [41] Prospective,
Randomised, Phase III
24 Imatinib 400 mga 159 47 400 mg 0% Yes No Yes No Yes Yes
Imatinib 600 mga 160 47 590 mg 0%
a) SID; b) BID; Q1) Was the method used to randomize patients described and adequate?; Q2) Was the method used for allocation concealment described and
adequate?; Q3) Were the detailed inclusion/exclusion criteria described?; Q4) Was the method used to ensure treatment blinding described and adequate?; Q5)
Were the patient baseline characteristics described? Q6) Were all analyses carried out using data from the Intention To Treat (ITT) patient group?
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intervals exclude one). The pooled one year CCyR
estimates for both dasatinib and nilotinb were very simi-
lar (dasatinib 100 mg 77.1% [95% CrI 67.2% to 85.3%],
nilotinib 600 mg 77.7% [95% CrI 64.8% to 87.7%],
nilotinib 800 mg 75.3% [95% CrI 61.0% to 86.1%]). TheFigure 1 Evidence network diagram.18 month estimates for dasatinib 100 mg and nilotinib
800 mg were again similar and significantly different to
imatinib 400 mg (dasatinib 100 mg 79.1% [95% CrI
72.0% to 85.1%], nilotinib 600 mg 83.1% [95% CrI 76.7%
to 88.4%], nilotinib 800 mg 80.0% [95% CrI 73.0% to
85.8%]).
Table 2 Data used in network meta-analysis




ENESTed 67.0% 63.0% 44.9%
Baccarani et al. 50.0% 51.9%
German CML Study IV 21.5% 33.5%




DASISION study group 83.4% 71.5%
ENESTed study group 80.1% 77.9% 65.0%
Baccarani et al. (2009) 58.3% 63.9%
German CML Study IV 49.8% 63.2%
Cortes et al. 2010 65.6% 69.9%
S0325 Intergroup Trial 82.0% 69.0%
SPIRIT 58.0% 65.0%
18 months
Dasatinib Study Group 88.6%
DASISION study group 78.0% 70.0%
ENESTed study group 85.0% 82.0% 74.0%
German CML Study IV 66.6% 73.8%
Major Molecular response
12 months
Bacarrani et al. (2009) 33.3% 39.8%
DASISION study group 45.9% 28.1%
ENESTed Study group 44.0% 43.1% 21.9%
German CML Study IV 30.8% 54.8%
Cortes et al. 2010 40.1% 46.4%
SPIRIT 38.0% 49.0%
S0325 Intergroup Trial 59.0% 43.0%
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At 12 months the odds of response for both dasatinib
and nilotinib were at least two times higher than for
imatinib 400 mg, with the results being significant
(dasatinib 100 mg 2.09, nilotinib 600 mg 2.87, nilotinib
800 mg 2.76; Table 4).
The one year MMR probabilities for dasatinib and
nilotinib were again shown to be significantly different
to imatinib 400 mg (Table 4) and similar to each other
(dasatinib 100 mg 51.1% [95% CrI 43.9% to 58.5%],
nilotinib 600 mg 58.7% [95% CrI 49.6% to 67.5%],
nilotinib 800 mg 57.8% [95% CrI 48.7% to 66.8%]).
Head to head comparison (dasatinib and nilotinib)
A summary of the odds ratios generated for all
endpoints when dasatinib was compared to nilotinib ispresented in Table 5. Regardless of nilotinib dose,
timepoint or endpoint of interest, all intervals include
one, and therefore it is not possible to differentiate the
two products in terms of either cytogenetic or major
molecular response.
Discussion
The short term clinical efficacy of imatinib, dasatinib
and nilotinib has been demonstrated in large, well
designed randomised trials [6,12,13]. Long term data
from the IRIS clinical trial is strongly supportive of the
argument that individuals who receive first line imatinib
will live many years longer than those who receive inter-
feron based therapy [7,9]. Due to the causal link between
prognosis and response to treatment it is highly likely,
given the significant differences observed in complete
Table 3 Complete cytogenetic response at 6, 12 and 18 months
Intervention Probability of response Response odds ratios
(Mean, 95% CrI) (Mean, 95% CrI)
CCyR at 6 months
Imatinib 400 mg daily 40.1% (Reference Category) N/A (Reference Category)
Dasatinib 100 mg daily 55.3% (22.9-86.7%) 2.98 (0.45-9.76)
Nilotinib 300 mg twice daily 60.7% (21.9-86.8%) 3.06 (0.42-9.85)
Nilotinib 400 mg twice daily 56.8% (20.4-85.5%) 2.77 (0.38-8.82)
Imatinib 800 mg daily 53.8% (35.7-71.8%) 1.92 (0.83-3.81)
CCyR at 12 months
Imatinib 400 mg daily 62.4% (Reference Category) N/A (Reference Category)
Dasatinib 100 mg daily 77.1% (67.2-85.3%) 2.16 (1.23-3.5)
Nilotinib 300 mg twice daily 77.7% (64.8-87.7%) 2.41 (1.11-4.29)
Nilotinib 400 mg twice daily 75.3% (61.0-86.1%) 2.06 (0.95-3.73)
Imatinib 800 mg daily 70.1% (62.1-76.9%) 1.45 (0.99-2.01)
CCyR at 18 months
Imatinib 400 mg daily 71.6% (Reference Category) N/A (Reference Category)
Dasatinib 100 mg daily 79.1% (72.0-85.1%) 1.55 (1.02-2.27)
Nilotinib 300 mg twice daily 83.1% (76.7-88.4%) 2.01 (1.31-3.00)
Nilotinib 400 mg twice daily 80.0% (73.0-85.8%) 1.63 (1.07-2.40)
Imatinib 800 mg daily 77.9% (71.9-83.2%) 1.43 (1.01-1.96)
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ond generation compared to first generation TKIs, that a
similar pattern will emerge when long term data from
DASISION and ENESTnd are published.
Despite the positive clinical profile of dasatinib and
nilotinib in the treatment of newly diagnosed CML, re-
imbursement agencies such as NICE and CADTH will
seek to explore the cost and benefit trade-offs associated
with the use of these products. From a reimbursement
perspective, poor or non-existent evidence is not a rea-
son for delaying or avoiding a decision, and so the use of
indirect comparison meta-analysis is becoming moreTable 4 Major molecular response at 12 months
Intervention Mean 95% LCrI 95% UCrI
Probability of response
Imatinib 400 mg daily 33.6% Reference category
Dasatinib 100 mg daily 51.1% 43.9% 58.5%
Nilotinib 300 mg twice daily 58.7% 49.6% 67.5%
Nilotinib 400 mg twice daily 57.8% 48.7% 66.8%
Imatinib 800 mg daily 48.1% 43.1% 53.1%
Response Odds Ratios
Imatinib 400 mg daily N/A Reference category
Dasatinib 100 mg daily 2.09 1.55 2.78
Nilotinib 300 mg twice daily 2.87 1.95 4.11
Nilotinib 400 mg twice daily 2.76 1.88 3.98
Imatinib 800 mg daily 1.84 1.50 2.24
LCrI: Lower boundary of derived credible interval; UCrI: Upper foundry of
derived credible interval.common in order to generate the relative efficacy
estimates required for a successful health technology as-
sessment in the absence of head to head data.
For all comparisons of dasatinib and nilotinib to
imatinib included in the meta-analysis, the derived
results are in line with those reported in the actual clin-
ical studies: dasatinib and nilotinib are clinically superior
to imatinib in terms of cytogenetic and major molecular
response at a range of time points. However, the key
value of this paper is in relation to the comparison of
dasatinib to nilotinib, since no head to head trial data
currently exists. We found no significant difference be-
tween the two treatment options in terms of either
CCyR or MMR at any of the time points where enough
data was available to inform the meta-analysis. Hence,
on the basis of the current literature, from the perspec-
tive of both clinicians and reimbursement agencies the
two products should be viewed as equally efficacious.
To the best of our knowledge, this is the first study to
use the combination of a full and thorough systematic
review of the literature and subsequent meta-analysis in-
corporating all available evidence rather than informa-
tion from single trials (e.g. DASISION and ENESTnd).
One other study has been published that attempted to
generate relative efficacy estimates for dasatinib and
nilotinib via the alteration of the results from one study
via a matching algorithm [42]. This approach neglects
the body of evidence in other trials – in particular the
S0325 Intergroup study [38] – and its acceptability
within the reimbursement agencies or with other meta-
Table 5 Head to head relative treatment effects expressed as odds ratios (mean, 95% CrI)
Dasatinib 100 mg Nilotinib 600 mg Nilotinib 800 mg
CCyR (6 months)
Dasatinib 100 mg N/A 0.76 (0.1, 9.31) 0.91 (0.12, 10.58)
Nilotinib 600 mg 1.32 (0.11, 9.58) N/A 1.2 (0.23, 5.5)
Nilotinib 800 mg 1.10 (0.09, 8.29) 0.84 (0.18, 4.27) N/A
CCyR (12 months)
Dasatinib 100 mg N/A 0.95 (0.41, 2.22) 1.09 (0.47, 2.60)
Nilotinib 600 mg 1.05 (0.45, 2.43) N/A 1.15 (0.58, 2.32)
Nilotinib 800 mg 0.92 (0.38, 2.13) 0.87 (0.43, 1.73) N/A
CCyR (18 months)
Dasatinib 100 mg N/A 0.77 (0.44, 1.36) 0.95 (0.54, 1.66)
Nilotinib 600 mg 1.30 (0.73, 2.29) N/A 1.23 (0.79, 1.92)
Nilotinib 800 mg 1.05 (0.60, 1.84) 0.81 (0.52, 1.27) N/A
MMolR (12 months)
Dasatinib 100 mg N/A 0.74 (0.45, 1.19) 0.76 (0.47, 1.22)
Nilotinib 600 mg 1.35 (0.84, 2.20) N/A 1.04 (0.74, 1.45)
Nilotinib 800 mg 1.31 (0.82, 2.13) 0.96 (0.69, 1.35) N/A
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presented in this paper are the most robust estimates
currently available to both clinicians and reimbursement
decision makers.
As noted previously, indirect comparison meta-analysis
respects randomisation in all included trials, uses all avail-
able evidence (both indirect and head to head) and, assum-
ing the trial populations are broadly homogeneous and
endpoints consistently defined, generates results that are
consistent with conventional meta-analyses when the
amount of head to head evidence is sufficient to allow both
approaches to be used. Further, the International Society
for Pharmacoeconomics and Outcomes Research (ISPOR)
set up a task force to generate ‘best practice’ guidelines to
be used in conducting and reporting an indirect compari-
son meta-analysis. These guidelines have been published
and the meta-analysis presented here was conducted to
meet the standard laid out in this document [25].
Despite the above mentioned strengths of the analysis,
there were a number of limitations. The primary concern
is that while the predicted 12 month CCyR values are
similar to the values in the ENESTnd study (reported:
80%/78%/65% for nilotinib 600 mg/800 mg and imatinib
400 mg: derived 77.7%/75.7%/62.4% respectively), the
predicted value for dasatinib (77.1%) is lower than
observed in either of the two identified studies
(DASISION: 83.4%, S0325: 82.0%). Given that the absolute
highest response rates of all included imatinib studies
were in these two studies, when the mean baseline
imatinib probability and relative efficacy estimates from
the meta-analysis are combined, the result was inevitable.
Hence the studies included may be heterogeneous,although no subgroup specific analyses were done to ex-
plore this topic. Further work via statistical comparisons
of inclusion criteria, baseline patient characteristics, etc. is
required to test this hypothesis although without access to
patient level data from multiple pharmaceutical compan-
ies such analyses may not be feasible.
Secondary concerns relate to the immaturity of the data-
base and to the limited number of studies identified. This
impacted on the project in two ways: i) through the large
amount of uncertainty surrounding the derived results
and ii) through the inability to generate meaningful evi-
dence networks for other clinically relevant outcome
measures (e.g. partial cytogenetic response, progression
free survival or overall survival). The majority of these
problems will be lessened over time with the publication
of either new studies or more information from existing
ones. However, given the target population and scarcity of
events it may never be possible to differentiate the survival
profiles (both progression free and overall) of the two sec-
ond generation products without a head to head trial.
Thirdly, only one manufacturer (Bristol-Myers Squibb)
had the opportunity to provide additional material to the
analysis, which could be perceived as non-transparent
and a bias in favour of dasatinib. As mentioned in the
results section, only material available in the public do-
main was used in the analysis and also that BMS
provided information on Nilotinib related studies.
Hence, the review maintained its transparency and no
bias existed.
It is important to note that the results were generated
using aggregate level trial data and hence should not be
interpreted as answering the questions ‘who should get
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questions would require either a meta-regression or re-
running of the analysis using subgroup specific data.
Conclusion
Regardless of whether head to head or indirect evidence
is considered relevant, treatment for newly diagnosed
CML with second generation TKIs such as dasatinib or
nilotinib results in significantly higher cytogenetic and
molecular response rates compared to imatinib 400 mg
daily. However, based on a thorough systematic review
of the literature and subsequent meta-analysis there is
no statistical difference in the six, 12 and 18 month
CCyR rates or the 12 month MMR rates for dasatinib
100 mg daily, nilotinib 600 mg daily and nilotinib
800 mg daily.
Additional file
Additional file 1: Search Strategies.
Abbreviations
CCyR: Complete Cytogenic Response; CML: Chronic Myeloid leukemia;
CrI: Credible Interval; MMR: Major Molecular Response; NMA: Network Meta-
Analysis; QALY: Quality Adjusted Life Year.
Competing interests
The study was sponsored by a consultancy agreement from Bristol-Myers
Squibb Ltd. SM, LB, NH, JC and VE work for an international consultancy firm
and have undertaken similar analyses for a number of pharmaceutical firms.
No restrictions were, however, placed by Bristol-Myers Squibb ltd. on the
design of the study, the choice of included articles or the presentation of
results. Publication of the manuscript is not contingent on sponsor approval
or censorship of the contents.
Authors’ contributions
SM, LB, IH and CD designed the study protocol. All authors reviewed
manuscripts and undertook data extraction. NH performed the network
meta-analysis and all authors contributed to the preparation of the
manuscript. All authors read and approved the final manuscript.
Author details
1Oxford Outcomes Ltd Seacourt Tower, West Way, Oxford, UK. 2Bristol-Myers
Squibb, 5 Research Parkway, Wallingford, CT 06492, USA. 3Bristol-Myers
Squibb, 100 Nassau Park Boulevard, Princeton, NJ 08540, USA.
Received: 8 February 2013 Accepted: 8 February 2013
Published: 19 February 2013
References
1. SEER Stat Fact Sheets: Chronic Myeloid Leukemia. National Cancer Institute
2012. http://seer.cancer.gov/statfacts/html/cmyl.html.
2. The Canadian Coordinating Office for Health Technology Assessment:
Issues in emerging Health Technologies. Imatimib Mesylate for Chronic
Myeloid Leukemia: What do we really know? http://www.cadth.ca/media/
pdf/192_imatinib_cetap_e.pdf 2009.
3. Dalziel K, Round A, Stein K, et al: Effectiveness and cost-effectiveness of
imatinib for first-line treatment of chronic myeloid leukaemia in chronic
phase: a systematic review and economic analysis. Health Technol Assess
2004, 8(28):1–120.
4. Baccarani M: Clinical implications of the recommendations of the
European LeukemiaNet. Presented at 14th Congress of the European
Hematology Association, Berlin, 4–7 June, 2009.5. National Comprehensive Cancer Network: NCCN Clinical Practice
Guidelines in Oncology: Chronic Myelogenous Leukemia. http://www.
nccn.org/professionals/physician_gls/PDF/cml.pdf 2009; (v.2.2010).
6. O’Brien SG, Guilhot F, Larson RA, et al: Imatinib compared with interferon
and low-dose cytarabine for newly diagnosed chronic-phase chronic
myeloid leukemia. N Engl J Med 2003, 348(11):994–1004.
7. Druker BJ, Guilhot F, O’Brien SG, et al: Five-year follow-up of patients
receiving imatinib for chronic myeloid leukemia. N Engl J Med 2003,
355(23):2408–2417.
8. Roy L, Guilhot J, Krahnke T, et al: Survival advantage from imatinib
compared with the combination interferon-alpha plus cytarabine in
chronic-phase chronic myelogenous leukemia: Historical comparison
between two phase 3 trials. Blood 2006, 108(5):1478–1484.
9. Hochhaus A, O’Brien SG, Guilhot F, et al: Six-year follow-up of patients
receiving imatinib for the first-line treatment of chronic myeloid
leukemia. Leukemia 2009, 23(6):1054–1061.
10. Mealing S, Scott DA, Taylor MJ, et al: The use of parametric survival
analysis to predict survival in newly diagnosed Chronic Myeloid
Leukemia (CML) patients. Presented at ESH ICMLF 13th International
Conference on Chronic Myeloid Leukemia - Biology and Therapy, Estoril,
Portugal, 22–25 September 2011.
11. Botteman M, Stephens J, Coombs J: Projecting the long-term survival of
newly diagnosed patients with chronic myeloid leukemia in chronic phase
recieving nilotinib or imatinib. Haematologica 2010, 95(Suppl 2):Abstr 0832.
12. Saglio G, Dong-Wook K, Issaragrisill S, et al: Nilotinib versus imatinib for
newly diagnosed Chronic Myeloid Leukemia. N Engl J Med 2010,
362(24):2251–2259.
13. Kantarjian H, Shah N, Hochhaus A, et al: Dasatinib versus imatinib in newly
diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010,
362(24):2260–2270.
14. Marin D, Milojkovic D, Olavarria E, et al: European LeukemiaNet criteria for
failure or suboptimal response reliably identify patients with CML in
early chronic phase treated with imatinib whose eventual outcome is
poor. Blood 2008, 112(12):4437–4444.
15. Braziel RM, Launder TM, Druker BJ, et al: Hematopathologic and
cytogenetic findings in imatinib mesylate-treated chronic myelogenous
leukemia patients: 14 months’ experience. Blood 2002, 100(2):435–441.
16. Kantarjian H, Sawyers C, Hochhaus A, et al: Hematologic and cytogenetic
responses to imatinib mesylate in chronic myelogenous leukemia. N Engl
J Med 2002, 346(9):645–652.
17. National Institute for Health and Clinical Excellence: Guide to the methods of
technology appraisal. http://www.nice.org.uk/niceMedia/pdf/TAP_Methods.
pdf 2008.
18. The Academy of Managed Care Pharmacy: The AMCP Format for Formulary
Submissions V3.0. http://www.amcp.org/data/jmcp/1007_121%2019%2009%
283%29.pdf 2010.
19. Canadian Agency for Drugs and Technologies in Health: Guidelines for the
Economic Evaluation of Health Technologies. http://www.cadth.ca/ 2006.
20. Higgins JP, Green S: Cochrane Handbook for Systematic Review of
Interventions. Hoboken, NJ: John Wiley & Sons Ltd; 2008.
21. Hawkins N, Scott DA, Woods BS, Thatcher N, No Study Left Behind: A network
meta-analysis in non-small-cell lung cancer demonstrating the importance
of considering all relevant data. Value Health 2009, 12(6):996–1003.
22. Ades AE, Sculpher MJ, Sutton AJ, et al: Bayesian methods for evidence
synthesis in cost-effectiveness analysis. Pharmacoeconomics 2006, 24(1):1–19.
23. Lu G, Ades AE: Combination of direct and indirect evidence in mixed
treatment comparisons. Stat Med 2004, 23(20):3105–3124.
24. Caldwell D, Ades AE, Higgins JP: Simultaneous comparison of multiple
treatments: combining direct and indirect evidence. Br Med J 2005,
331(7521):897–900.
25. Hoaglin DC, Hawkins N, Janssen J, et al: Conducting indirect-treatment
comparison and network meta-analysis studies: report of the ISPOR Task
Force on indirect comparisons good research practices - Part 2.
Value Health 2011, 14:429–437.
26. Song F, Loke YK, Walsh T, et al: Methodological problems in the use of
indirect comparisons for evaluating healthcare interventions: survey of
published systematic reviews. Br Med J 2009, 338:b1147.
27. The BUGS project: http://www.mrc-bsu.cam.ac.uk/bugs 2011.
28. The R project for statistical computing. www.r-project.org, 2011.
29. Kantarjian H, Shah N, Hochhaus A, et al: Dasatinib compared to imatinib
(IM) in patients (pts) with newly diagnosed Chronic Myelogenous
Mealing et al. Experimental Hematology & Oncology 2013, 2:5 Page 9 of 9
http://www.ehoonline.org/content/2/1/5Leukemia in Chronic Phase (CML-CP): 12 month efficacy and safety from
the phase 3 Dasision study. J Clin Oncol 2010, 28(18(s)):abstr LBA6500.
30. Baccarani M, Shah N, Kantarijan H, et al: Dasatinib compared to imatinib in
patients with newly diagnosed chronic-phase chronic myelogenous
leukemia (CML-CP): results from the randomized phase 3 DASISION trial.
Haematologica 2010, 95(Suppl 2):Abstr 0560.
31. Shah N, Kantarijan H, Hochhaus A, et al: Dasatinib versus imatinib in
patients with newly diagnosed chronic myeloid leukemia in chronic
phase (CML-CP) in the DASISION trial: 18-month follow up. Blood 2010,
116(ASH Annual Meeting Abstracts):Abstr 206.
32. Baccarani M, Rosti G, Castagnetti F, et al: Comparison of imatinib 400 mg
and 800 mg daily in the front-line treatment of high-risk, philadelphia-
positive chronic myeloid leukemia: a European LeukemiaNet study.
Blood 2009, 113(19):4497–4504.
33. Haferlach C, Hehlmann R, Lauseker M, et al: Treatment optimization by
high-dose imatinib: randomised comparison of imatinib 800 mg versus
imatinib 400 mg+/−IFM in newly diagnosed BCR-ABL positive chronic
phase (CP) CML: the German CML-study IV. J Clin Oncol 2010, 28(15s):
Abstr 6517.
34. Hehlmann R, Jung-Munkwitz S, Lauseker M, et al: Superior CMR-rates with
tolerability-adapted imatinib 800 mg vs. 400 mg vs. 400 mg + IFN in
CML: the randomised German CML-study IV. Blood 2010, 116(ASH Annual
Meeting Abstracts):Abstr 357.
35. Hughes TP, Hochhaus A, Saglio G, et al: ENESTnd update: continued
superiority of nilotinib versus imatinib in patients with newly diagnosed
Chronic Myeloid Leukemia in Chronic Phase (CML-CP). Blood 2010,
116(ASH Annual Meeting Abstracts):Abstr 207.
36. Larson RA, le Coutre PD, Reiffers J, et al: Comparison of nilotinib and
imatinib in patients (pts) with newly diagnosed Chronic Myeloid
Leukemia in Chronic Phase (CML-CP): ENESTnd beyond one year.
J Clin Oncol 2010, 28(15s):Abstr 6501.
37. Saglio G, Dong-Wook K, Issaragrisill S, et al: Nilotinib demonstrates superior
efficacy compared with imatinib in patients with newly diagnosed chronic
myeloid leukemia in chronic phase: results from the International
Randomised Phase III ENESTnd trial. Blood 2009, 114(ASH Annual Meeting
Abstracts):Abstr LBA-1.
38. Radich JP, Kopecky KJ, Kamel-Reid S, et al: A randomised phase II trial of
dasatinib 100 mg vs. Imatinib 400 mg in newly diagnosed Chronic
Myeloid Leukemia in Chronic Phase (CML-CP): the S0325 intergroup trial.
Blood 2010, 116(ASH Annual Meeting Abstracts):Abstr LBA-6.
39. Petzer AL, Wolf D, Fong D, et al: High-dose imatinib improves cytogenetic
and molecular remissions in patients with pretreated Philadelphia-
positive, BCR-ABL-positive chronic phase chronic myeloid leukemia: first
results from the randomized CELSG phase III CML 11 “ISTAHIT” study.
Haematologica 2010, 95(6):908–913.
40. Cortes JE, Baccarani M, Guilhot F, et al: Phase III, randomized, open-label
study of daily imatinib mesylate 400 mg versus 800 mg in patients with
newly diagnosed, previously untreated chronic myeloid leukemia in
chronic phase using molecular end points: tyrosine kinase inhibitor
optimization and selectivity study. J Clin Oncol 2010, 28(3):424–430.
41. Preudhomme C, Guilhot J, Nicolini FE, et al: Imatinib plus Peginterferon
Alfa-2a in Chronic Myeloid Leukemia. N Engl J Med 2010, 363(26):2511–2521.
42. Signorovitch JE, Wu EQ, Betts KA, et al: Comparative efficacy of nilotinib
and dasatinib in newly diagnosed chronic myeloid leukemia: a
matching-adjusted indirect comparison of randomized trials. Curr Med
Res Opin 2011, 27(6):1263–1271.
doi:10.1186/2162-3619-2-5
Cite this article as: Mealing et al.: The relative efficacy of imatinib,
dasatinib and nilotinib for newly diagnosed chronic myeloid leukemia:
a systematic review and network
meta-analysis. Experimental Hematology & Oncology 2013 2:5.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
